ArticleTranslational cancer research2021
Aspirin-induced long non-coding RNA suppresses colon cancer growth.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Assessment of Expression LncRNA-xloc-000303, lncRNA-LOC152578 and hsa-miR-29a in Patients Diagnosed With Colon Cancer in the Pre-Treatment Stage.Cancer reports (Hoboken, N.J.) · 2025Article
- Pathway polygenic risk scores (pPRS) for the analysis of gene-environment interaction.PLoS genetics · 2025Article
- A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches.Clinical epigenetics · 2025Review
- LncRNAs in Kawasaki disease and Henoch-Schönlein purpura: mechanisms and clinical applications.Molecular and cellular biochemistry · 2024Review
- Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.Cellular and molecular life sciences : CMLS · 2022Review
- Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease.Journal of molecular and cellular cardiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo study the effect of long non-coding RNAs (lncRNA) on aspirin-treated colon cancer cells.
methodsTo study the changes of lncRNA in aspirin-treated colon cells by microarray analysis, real-time quantitative PCR (qPCR) was used to verify the expression of selected lncRNA and mRNA. The effects of aspirin on the proliferation and metastasis of the siRNA transfected cells and control colon cancer cells were detected by Cell Counting Kit-8 (CCK-8) and Transwell experiments. Bioinformatics tools were employed to analyze the potential function of lncRNA.
resultsCompared with the control group, aspirin inhibited the proliferation and metastasis of colon cancer cells. Microarray analysis showed that a total of 10,568 lncRNAs and 22,126 mRNAs were noticeably expressed in the aspirin-treated group (≥1.5-fold, P<0.05). The qPCR results showed that lncRNA and mRNA expressions were consistent with microarray analysis. The analysis of the co-expression network profiles of 58 lncRNA and 101 mRNA differential genes showed a total of 158 nodes and 791 connections. Analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways revealed that a variety of lncRNAs (NEAT1, LOC152578) were involved in the inhibition mechanism of aspirin in colon cancer.
conclusionslncRNA NEAT1 and LOC152578 are involved in the inhibition of tumor cell growth and metastasis by aspirin. The results of these analyses will help us further understand the mechanism of action of aspirin and the roles of lncRNAs in the prevention and treatment of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.